

General Announcement::Trendlines Signs Framework Agreement with Japanese Multinational Medical Device Co

Issuer & Securities

Issuer/ Manager	THE TRENDLINES GROUP LTD.
Securities	THE TRENDLINES GROUP LTD. - IL0011328858 - 42T
Stapled Security	No

Announcement Details

Announcement Title	General Announcement
Date & Time of Broadcast	11-Feb-2016 19:42:55
Status	New
Announcement Sub Title	Trendlines Signs Framework Agreement with Japanese Multinational Medical Device Co
Announcement Reference	SG160211OTHRYF58
Submitted By (Co./ Ind. Name)	Yosef Ron
Designation	Joint Company Secretary
Description (Please provide a detailed description of the event in the box below)	Please see attached.
Attachments	<p>Trendlines MMC Agreement 11_02_2016.pdf</p> <p>Total size =88K</p>

Like

THE TRENDLINES GROUP LTD.

(Incorporated in Israel)

(Company Registration No. 513970947)

**The Trendlines Group Ltd. Signs Collaboration Framework Agreement with
Japanese Multinational Medical Device Company**

The board of directors (the “**Board**”) of The Trendlines Group Ltd. (the “**Company**” or “**The Trendlines Group**”) and, together with its subsidiaries and associated companies, the “**Group**”) wishes to announce that the Company signed a definitive collaboration framework agreement (the “**Agreement**”) with a multinational medical device corporation (“**MMC**”) headquartered in Japan. Under the Agreement, the Company and the MMC shall mutually identify certain clinical opportunities in agreed fields as determined or to be determined in each statement of work which has been incorporated or will be incorporated to the Agreement. The Company’s Trendlines Labs unit will develop innovative medical device products for manufacture and marketing by the MMC.

Background

Trendlines Labs, the in-house innovation centre of The Trendlines Group, creates and develops technologies and products to meet critical unmet needs. Trendlines Labs’ multidisciplinary team of scientists, engineers, and medical professionals brings extensive project management experience to its focused, efficient approach to innovation.

Matching The Trendlines Group’s innovation and product development expertise with the Japanese MMC’s depth of manufacturing experience and market reach, the Agreement will serve to expand and enhance the extensive product portfolio of this market-leading MMC.

Principal Terms of the Agreement

Under the Agreement, risk is shared between the parties and the Company may receive milestone payments from the MMC for the achievement of specific milestones during the development period. In addition, the MMC will pay royalties to The Trendlines Group for a specific period from the worldwide sale of products developed under the Agreement once the developed products come to market.

Under the Agreement, all intellectual property (“**IP**”) developed by the Company and arising from the Agreement will be the property of the MMC. The Company will be granted an exclusive, perpetual, worldwide, royalty-free license to use the IP for products that do not compete with the MMC’s products for which the IP was developed. Should the MMC discontinue any specific development program under the Agreement, the IP will be retained by the Company, which will owe the MMC a royalty, up to an agreed limit, from any proceeds earned based on such IP.

Financial Impact

The Agreement is not expected to have any material impact on the Group's earnings per share and net tangible assets per share for the financial year ending 31 December 2016.

Interest of Directors and Substantial Shareholders

None of the Company's Directors, substantial shareholders and any of their respective associates has any interest, direct or indirect (other than through their shareholdings in the Company), in the Agreement.

BY ORDER OF THE BOARD THE TRENDLINES GROUP LTD

Yosef Ron,
Joint Company Secretary

11 February 2016

*The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").*

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.